The board (the "Board") of directors (the "Directors", each a "Director") of Genor Biopharma Holdings Limited (the "Company", together with its subsidiaries, the "Group") announced that Mr. Chen Yu ("Mr. Chen") has tendered his resignation as a non-executive Director and an authorised representative ("Authorised Representative") of the Company under Rule 3.05 of The Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") due to his decision to devote more time on his other business commitments, with effect from 2 January 2024. The Board announced that Mr. Yu Tieming ("Mr. Yu") is appointed as a non-executive Director and an Authorised Representative with effect from 2 January 2024. Mr. Yu, aged 42, is currently a partner at Hillhouse Investment.

From July 2006 to October 2011, Mr. Yu served as the manager of Global Capital Market Group at PricewaterhouseCoopers Zhong Tian LLP. From October 2011 to May 2014, Mr. Yu served as the manager of Capital Market and Accounting Consulting Services at PricewaterhouseCoopers of Sydney. From May 2014 to February 2016, Mr. Yu served as the senior investment manager at Keytone Ventures.

Since February 2016, Mr. Yu has joined Hillhouse Investment and now serves as a partner. From April 2021 to May 2022, Mr. Yu has also served as a director of Zhejiang Hisun Pharmaceutical Co. Ltd., a company listed on the Shanghai Stock Exchange.

Mr. Yu holds a Bachelor Degree in Financial Management from Northern Jiaotong University (currently known as Beijing Jiaotong University), a Master's Degree in Accounting from Beijing Jiaotong University and an EMBA Degree from China Europe International Business School (CEIBS). Mr. Yu is also a member of the Chinese Institute of Certified Public Accountants (CICPA) and CPA Australia. Following Mr. Chen's resignation as a non-executive Director, he has ceased to be a member of the compensation committee of the Board (the "Compensation Committee").

Mr. Yu, the newly appointed non-executive Director, is appointed as a member of the Compensation Committee, with effect from 2 January 2024. Accordingly, the Compensation Committee comprises Mr. Chen Wen as the chairman of the Compensation Committee, and Mr. Fung Edwin and Mr. Yu as members of the Compensation Committee.